Articles tagged "HLA antibodies"

2018 American Transplant Congress
Epitope/Eplet Mismatch in Pediatric Renal Transplantation and Development of Donor Specific Antibody
R. George,¹ H. Sullivan,² R. Garro,¹ P. Winterberg,¹ B. Warshaw,¹ H. Gebel,² R. Bray.²
¹Pediatric Nephrology, Emory University & Children's Healthcare of Atlanta, Atlanta, GA; ²Dept. of Pathology, Emory Transplant Center, Emory University, Atlanta, GA.
Background: De-novo donor specific antibody (DSA) is one of the strongest independent predictors of graft loss with HLA mismatching being a major risk factor for…
2018 American Transplant Congress
Increasing the Donor Pool for Highly Sensitized Patients with Allele Specific Antibodies: Optimizing the Virtual Crossmatch (vXM)
A. Zhang,¹ Z. Zaky,² J. Africa,³ D. Good,¹ R. Bray,⁴ H. Gebel.⁴
¹Allogen Laboratories, Cleveland Clinic, Cleveland; ²Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland; ³Transplant Surgery, Charleston Area Medical Center, Charleston; ⁴Pathology & Laboratory Medicine, Emory University, Atlanta.
Background:Since implementation of the current Kidney Allocation System, highly sensitized patients with 98-100% cPRA (HSPs) are receiving ~10% of deceased donor kidneys compared to <2%…
2018 American Transplant Congress
Biopsy Correlates of DSA in Antibody-Mediated Rejection: C4d vs Microvascular Inflammation Scores
C. Harris, L. Anderson, R. Khaim, J. Choudhuri, R. Shapiro, S. Florman, F. Salem, M. Menon.
Icahn School of Medicine at Mount Sinai, New York, NY.
Background: The diagnosis of antibody-mediated rejection (AMR) requires the presence of both the histologic features of AMR as well as donor-specific antibodies (DSA). Whether anti-HLA…
2018 American Transplant Congress
Generation of Calculated Panel-Reactive Antibody Values Using a Reference Panel of Bone Marrow Donors
E. Kransdorf,¹ L. Gragert,^2,4 M. Pando,³ N. Kaur,² J. Patel,¹ I. Kim,¹ X. Zhang,¹ M. Maiers,⁴ J. Kobashigawa.¹
¹Cedars-Sinai Medical Center, Los Angeles, CA; ²Tulane University School of Medicine, New Orleans, LA; ³Baylor Scott & White, Temple, TX; ⁴National Marrow Donor Program, Minneapolis, MN.
Introduction: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. The reference…
2018 American Transplant Congress
Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipients
S. Wan,^1,2 S. Chadban,^1,2 K. Wyburn.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia.
BACKGROUND: Donor specific antibodies (DSA) have been implicated in the development of acute rejection (AR) and graft dysfunction in kidney transplant recipients (KTx). However, limited…
2018 American Transplant Congress
Safety and Efficacy of Tocilizumab (anti-IL6R, TCZ) Therapy in the Treatment of Chronic Antibody Mediated Rejection (cABMR) in Pediatric Renal Transplant Recipients
D. Puliyanda, I. Kim, J. Choi, M. Haas, X. Zhang, A. Vo, H. Pizzo, S. Jordan.
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA.
Background: Development of de novo Donor specific antibodies (DSA) post renal transplantation puts pediatric patients(pts) at risk for ABMR and allograft failure (Kim JJ AJT…
2018 American Transplant Congress
Follow Up of Patients Treated with the IgG Endopeptidase (IdeS) for Desensitization and HLA Incompatible (HLAi) Kidney Transplantation
S. Jordan,¹ J. Choi,¹ E. Huang,¹ R. Najjar,¹ A. Peng,¹ X. Zhang,¹ S. Louie,¹ M. Haas,² S. Sethi,¹ I. Kim,¹ A. Vo.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Donor-specific antibodies (DSAs) create an immunologic barrier to transplantation. This prevents transplantation for a significant percentage of highly-HLA sensitized patients (HS). Current desensitization therapies are…
2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
A. Vo,¹ O. Aubert,² H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ J. Choi,¹ K. Lim,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research Center for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…
2018 American Transplant Congress
Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients
E. Kincaide,^1,2,3 K. Hitchman,^1,3 R. Hall,^1,2,3 I. Yamaguchi,³ B. Crowther.^1,2,3
¹University Health System, San Antonio, TX; ²College of Pharmacy, Pharmacotherapy Division, The University of Texas at Austin, Austin, TX; ³UT Health San Antonio, San Antonio, TX.
Purpose: Characterize class I and class II donor specific antibodies (DSA) response to acute antibody mediated rejection (AMR) treatment in pediatric kidney transplant recipients (KTR).Methods:…
2018 American Transplant Congress
No Deleterious Effect from the Presence of Donor Specific Antibodies (DSA) or Positive Flow Cytometry Crossmatch (FCXM) on the Outcomes of Simultaneous Liver-Kidney (SLK) Transplant Recipients
H. Khamash, A. Kumar, B. Aqel, R. Heilman, A. Jaramillo, K. Reddy, A. Moss.
Mayo Clinic Arizona, Phoenix.
SLK transplant recipients have excellent outcomes that rival kidney alone recipients in terms of graft and patient survival and have better outcomes in terms of…